Results 161 to 170 of about 73,761 (306)

MANAGEMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN PEDIATRIC LIVER TRANSPLANT RECIPIENTS RECEIVING PRIMARY TACROLIMUS (FK506) THERAPY

, 1998
Thomas V. Cacciarelli, Michael Green, Ronald Jaffe, George Mazariegos, Amit Jain, John J. Fung, Jorge Reyes   +6 more
openalex   +1 more source

Combination Therapy with Oral Tacrolimus (FK506) and Azathioprine or 6-Mercaptopurine for Treatment-Refractory Crohnʼs Disease Perianal Fistulae [PDF]

, 1999
Philip W. Lowry, Amy L. Weaver, William J. Tremaine, William J. Sandborn   +3 more
openalex   +1 more source

Tacrolimus versus cyclosporine immunosuppression in lung transplantation: a systematic review and meta-analysis. [PDF]

BMJ Open Respir Res
Pitre T, Gurupatham S, Desai K, Binnie M, Martinu T, Juvet S, Zeraatkar D.   +6 more
europepmc   +1 more source

PEDIATRIC RENAL TRANSPLANTATION UNDER TACROLIMUS-BASED IMMUNOSUPPRESSION1

, 1999
Ron Shapiro, Velma P. Scantlebury, Mark L. Jordan, Carlos Vivas, Demetrius Ellis, Susan Lombardozzi-Lane, Nisan Gilboa, H. Albin Gritsch, William Irish, Jerry McCauley, John J. Fung, Thomas R. Hakala, Richard L. Simmons, Thomas E. Starzl   +13 more
openalex   +1 more source

Invasive Aspergillosis in Mice Immunosuppressed with Cyclosporin A, Tacrolimus (FK506), or Sirolimus (Rapamycin) [PDF]

, 1997
Kevin P. High, Ronald G. Washburn
openalex   +1 more source

Short (2‐Hour) Non‐Oxygenated End‐Ischemic Hypothermic Perfusion Versus Cold Storage in the Setting of Renal Transplantation

Artificial Organs, EarlyView.
EI‐HMP enhances urine output and reduces ICU stay in kidney transplant patients, particularly in ECD grafts, but does not significantly impact long‐term survival or dialysis avoidance. These short‐term benefits suggest EI‐HMP may improve early recovery, although its long‐term efficacy requires further investigation through randomized controlled trials.
Franco Ruberto, Quirino Lai, Mario Piazzolla, Luca Poli, Veronica Zullino, Giulia Diamantini, Matteo Brisciani, Francesco Giovanardi, Fabio Melandro, Silvia Quaresima, Massimo Rossi, Manuela Garofalo, Francesco Pugliese   +12 more
wiley   +1 more source

Long-term effectiveness and safety of methotrexate-tacrolimus combination therapy versus methotrexate monotherapy in reducing rheumatoid arthritis flares after TNF inhibitor discontinuation: a retrospective cohort study. [PDF]

BMC Rheumatol
Naniwa T, Kajiura M.
europepmc   +1 more source

Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation

, 1999
Donna Przepiorka, I. Khouri, Cindy Ippoliti, Naoto T. Ueno, Rakesh Mehra, M Körbling, Sergio Giralt, James Gajewski, Harald E. Fischer, Michèle L. Donato, Karen R. Cleary, David F. Claxton, K-W Chan, Ira Braunschweig, Koen van Besien, BS Andersson, Paolo Anderlini, R. Champlin   +17 more
openalex   +1 more source

Real‐World Effectiveness and Safety of Mirikizumab Induction Therapy in Patients With Ulcerative Colitis: A Multicentre Retrospective Observational Study

Alimentary Pharmacology &Therapeutics, EarlyView.
This real‐world multicenter study assessed the short‐term effectiveness and safety of mirikizumab induction therapy in ulcerative colitis patients. Among 52 patients, the median partial Mayo score significantly decreased from week 0 to 12, and 44.2% achieved clinical remission, with no treatment‐related discontinuations or deaths.
Yasuhiro Takagi, Toshiyuki Sato, Takanori Nishiguchi, Akira Nogami, Masataka Igeta, Soichi Yagi, Maiko Ikenouchi, Mikio Kawai, Koji Kamikozuru, Yoko Yokoyama, Toshihiko Tomita, Hirokazu Fukui, Masayuki Fukata, Taku Kobayashi, Shinichiro Shinzaki   +14 more
wiley   +1 more source

Topical tacrolimus for the amelioration of breast cancer-related lymphedema (TACLE Trial): a study protocol for a randomized, double-blind, placebo-controlled phase II/III trial. [PDF]

Trials
Hansen FG, Jørgensen MG, Thomsen JB, Sørensen JA.   +3 more
europepmc   +1 more source